Evidence map›Paper›PMID 42488884›Full record

ArticlePathology oncology research : POR2025

Evaluating an RNA-based test for proliferation assessment and recurrence prediction in early HR+/HER2- breast cancer.

Marcus Vetter, Elena Diana Chiru, Anna Gasior, Joanna Gorniak, Sara Rollinson, Leanne Gough, Mathew Harrison, Martina Sonderegger-Stalder, Matthias Matter, Simone Muenst and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology oncology research : POR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marcus Vetter *Center for Oncology and Hematology, Medical University Clinic, Cantonal Hospital Basel-Land, Liestal, Switzerland.
Elena Diana Chiru *Center for Oncology and Hematology, Medical University Clinic, Cantonal Hospital Basel-Land, Liestal, Switzerland.
Anna GasiorAPIS Assay Technologies Ltd., Manchester, United Kingdom.
Joanna GorniakAPIS Assay Technologies Ltd., Manchester, United Kingdom.
Sara RollinsonAPIS Assay Technologies Ltd., Manchester, United Kingdom.
Leanne GoughAPIS Assay Technologies Ltd., Manchester, United Kingdom.
Mathew HarrisonAPIS Assay Technologies Ltd., Manchester, United Kingdom.
Martina Sonderegger-Stalder *Center for Oncology and Hematology, Medical University Clinic, Cantonal Hospital Basel-Land, Liestal, Switzerland.
Matthias MatterMedical Faculty, Basel University, Basel, Switzerland.
Simone MuenstMedical Faculty, Basel University, Basel, Switzerland.
Christian KurzederBreast Care Center, University Hospital Basel, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multigene signatures like Oncotype DX and Prosigna Prediction Analysis of Microarray 50 (PAM50) help estimate distant recurrence risk in patients with luminal breast cancer receiving endocrine therapy. Determining the benefit of adjuvant chemotherapy, tests are costly and not always supported through reimbursement. We aimed to assess the utility of the APIS Breast cancer subtyping kit (BCSK) and its proliferation score (PS), as a potential prognostic assay. We analysed 141 adult patients with early luminal HER2- breast cancer diagnosed between 2020 and 2022 at Cantonal Hospital Basel-Land and Basel University Hospital. All patients had a valid OncotypeDX

Indexed as

Biomarkers, TumorBreast NeoplasmsNeoplasm Recurrence, LocalAdultAgedCell ProliferationErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansMiddle AgedPrognosisReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesteronebreast cancerKi67molecular subtypingOncotype DXproliferationProsigna PAM50recurrence riskrecurrence score

Identifiers

PMID42488884
PMCPMC13388230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.